<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40858059</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>10</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-7714</ISSN><JournalIssue CitedMedium="Internet"><Volume>96</Volume><PubDate><Year>2025</Year><Season>Sep-Oct</Season></PubDate></JournalIssue><Title>General hospital psychiatry</Title><ISOAbbreviation>Gen Hosp Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Psilocybin-assisted psychotherapy for depression and anxiety associated with life threatening illness: A phase 2b randomized controlled trial.</ArticleTitle><Pagination><StartPage>322</StartPage><EndPage>331</EndPage><MedlinePgn>322-331</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.genhosppsych.2025.08.001</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0163-8343(25)00157-4</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Psilocybin-assisted psychotherapy may offer a novel approach to treating depression, anxiety, and existential distress in individuals with life threatening illnesses, where current treatments show limited efficacy.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate the efficacy and safety of psilocybin-assisted psychotherapy versus active placebo and psychotherapy in adults with life-threatening illnesses.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Double-blind, randomized controlled phase 2b trial (RCT) with an open-label extension and 6-month follow-up (January 2020 - October 2023).</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Single-site study at a tertiary hospital's palliative care department (St. Vincent's Hospital Melbourne affiliated with the University of Melbourne).</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">Adults aged 18-80 with a life-threatening illness and clinically significant depression and/or anxiety.</AbstractText><AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">Participants were randomized to receive 25&#xa0;mg psilocybin or 100&#xa0;mg niacin (active placebo), alongside three preparatory psychotherapy and six post-dose integration psychotherapy sessions. After 6-7&#xa0;weeks post double blind dose, all participants received 25&#xa0;mg psilocybin in an open-label extension, enabling a two dose versus one dose group comparator. Participants were followed up to 26&#xa0;weeks post open label dose.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="METHODS">Primary outcome was change in depression and anxiety symptoms, assessed using the Hospital Anxiety and Depression Scale (HADS), from baseline to 6-7&#xa0;weeks post-dose. Key secondary outcomes included the Beck Depression Inventory-II (BDI-II) and the State-Trait Anxiety Inventory - State version (STAI-S), which provided complementary, dimensional measures of depression and anxiety over the same time period. Additional secondary outcomes included Death Attitudes Profile, WHOQOL-BREF, State-Trait Anxiety Inventory (STAI-Trait scale), Mystical Experiences Questionnaire, and Persisting Effects Questionnaire. Exploratory outcomes included spiritual well-being, hopelessness, demoralization, and HADS-Trait scores.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Thirty-five participants (mean age 56.0; 54.3&#xa0;% female) were randomized (psilocybin: n&#xa0;=&#xa0;17; placebo: n&#xa0;=&#xa0;18). At 6-7&#xa0;weeks, psilocybin produced significantly greater reductions in HADS depression (B&#xa0;=&#xa0;-2.49; P&#xa0;=&#xa0;.02; d&#xa0;=&#xa0;1.12), BDI-II (B&#xa0;=&#xa0;-7.56; P&#xa0;=&#xa0;.004; d&#xa0;=&#xa0;2.97), and STAI-State anxiety (B&#xa0;=&#xa0;-12.59; P&#xa0;=&#xa0;.005; d&#xa0;=&#xa0;4.51) compared to placebo. Benefits were sustained at 26&#xa0;weeks. Exploratory outcomes demonstrated enhanced spiritual well-being, quality of life, and significant reductions in demoralization, death anxiety and hopelessness. No serious treatment-emergent adverse events occurred. Psilocybin was associated with more mild-to-moderate adverse events. One participant withdrew due to anxiety during dosing.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">Psilocybin-assisted psychotherapy appears safe and may offer durable relief from depression and anxiety in individuals with a life-threatening illness.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ross</LastName><ForeName>Margaret L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Department of Psychosocial Cancer Care, St. Vincent's Hospital Melbourne, Fitzroy, VIC, Australia; Palliative Medicine Unit, St. Vincent's Hospital Melbourne, Fitzroy, VIC, Australia. Electronic address: Margaret.ross@svha.org.au.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iyer</LastName><ForeName>Ravi</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Centre for Mental Health &amp; Brain Sciences, Swinburne University, Hawthorn, VIC, Australia; Mental Health Australia General Clinical Trials Network (MAGNET), Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Martin L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Centre for Mental Health &amp; Brain Sciences, Swinburne University, Hawthorn, VIC, Australia; Psychedelic Research in Science and Medicine (PRISM), Melbourne, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boughey</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Palliative Medicine Unit, St. Vincent's Hospital Melbourne, Fitzroy, VIC, Australia; Centre for Palliative Care, St Vincent's Hospital Melbourne and University of Melbourne, Melbourne, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Callaghan</LastName><ForeName>Clare</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Psychosocial Cancer Care, St. Vincent's Hospital Melbourne, Fitzroy, VIC, Australia; Palliative Medicine Unit, St. Vincent's Hospital Melbourne, Fitzroy, VIC, Australia; Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hiscock</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Anaesthesia, Mercy Hospital for Women, Melbourne, VIC, Australia; Department of Obstetrics and Gynaecology, University of Melbourne, Melbourne, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dwyer</LastName><ForeName>Justin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychosocial Cancer Care, St. Vincent's Hospital Melbourne, Fitzroy, VIC, Australia; Palliative Medicine Unit, St. Vincent's Hospital Melbourne, Fitzroy, VIC, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Gen Hosp Psychiatry</MedlineTA><NlmUniqueID>7905527</NlmUniqueID><ISSNLinking>0163-8343</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>2RV7212BP0</RegistryNumber><NameOfSubstance UI="D011562">Psilocybin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006213">Hallucinogens</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011562" MajorTopicYN="Y">Psilocybin</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011613" MajorTopicYN="Y">Psychotherapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006213" MajorTopicYN="Y">Hallucinogens</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001007" MajorTopicYN="Y">Anxiety</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016638" MajorTopicYN="Y">Critical Illness</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="Y">Depression</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017063" MajorTopicYN="Y">Outcome Assessment, Health Care</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Dr. Margaret Ross reports financial support was provided by PRISM - Psychedelic Research In Science and Medicine. Dr. Martin L Williams reports financial support was provided by Vasudhara Foundation. Author has been an unpaid member of two scientific advisory committees &#x2013; Psychedelic Institute of Australia; MIND Foundation - Margaret Ross If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>7</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>11</Day><Hour>0</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>27</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>26</Day><Hour>18</Hour><Minute>9</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40858059</ArticleId><ArticleId IdType="doi">10.1016/j.genhosppsych.2025.08.001</ArticleId><ArticleId IdType="pii">S0163-8343(25)00157-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>